Retatrutide Dosing: Why It Differs From Other GLP-1 Peptides
Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously. This triple mechanism produces stronger metabolic effects than single or dual agonists — and also means dosing must be handled with more conservative escalation to allow receptor adaptation at each level.
Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide's glucagon receptor agonism introduces additional thermogenic and metabolic activity. The Phase 2 trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) used a stepped escalation protocol designed to minimise gastrointestinal adverse events while progressively increasing receptor engagement.
Key pharmacokinetic data Half-life: ~6 days (once-weekly subcutaneous injection) · Receptors: GLP-1R + GIPR + GcgR · Phase 2 maximum dose tested: 12mg/week · Phase 3 TRIUMPH trials: ongoing as of 2026
For full mechanistic background, see the Retatrutide Research Guide. For reconstitution and storage, see the Peptide Reconstitution & Storage Guide.
Phase 2 Dosing Schedule (NEJM 2023)
The Jastreboff et al. Phase 2 trial (NEJM, 2023) enrolled adults with obesity across four dose cohorts plus placebo. All participants began at 0.5mg/week and escalated per the schedule below. Doses were administered once weekly by subcutaneous injection.
| Dose cohort | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 | Weeks 13–16 | Weeks 17–20 | Weeks 21–48 |
|---|---|---|---|---|---|---|
| 1mg | 0.5mg | 1mg | 1mg | 1mg | 1mg | 1mg |
| 4mg | 0.5mg | 1mg | 2mg | 4mg | 4mg | 4mg |
| 8mg | 0.5mg | 1mg | 2mg | 4mg | 8mg | 8mg |
| 12mg | 0.5mg | 1mg | 2mg | 4mg | 8mg | 12mg |
Weight loss by cohort 1mg: −8.7% · 4mg: −17.1% · 8mg: −19.2% · 12mg at 48 weeks: −24.2% mean body weight reduction (Jastreboff 2023, NEJM).
Understanding the Escalation Rationale
Graduated escalation reduces gastrointestinal adverse events by giving receptors time to adapt at each dose level. Each 4-week step corresponds to a distinct pharmacological adaptation window:
| Step | Duration | Primary adaptation |
|---|---|---|
| 0.5mg → 1mg | 4 weeks | GLP-1R satiety signalling onset |
| 1mg → 2mg | 4 weeks | Enhanced GIPR co-agonism |
| 2mg → 4mg | 4 weeks | Increased GcgR thermogenic contribution |
| 4mg → 8mg | 4 weeks | Full triple-receptor engagement at clinical range |
| 8mg → 12mg | 4 weeks | Maximum Phase 2 dose — Phase 3 dose selection ongoing |
The Phase 2 protocol allowed a dose hold (staying at the current step for an additional 4 weeks if GI events were significant) and a dose reduction (stepping back one level for intolerable AEs) before re-escalation — both tools applicable to research protocol design.
Reconstitution and Injection Volume Reference
RetaLABS Retatrutide is supplied lyophilised in 20mg and 30mg vials. Standard reconstitution: add bacteriostatic water to achieve 10 mg/mL concentration.
20mg vial + 2mL bacteriostatic water = 10 mg/mL:
| Weekly dose | Injection volume | U100 syringe units | Doses per 20mg vial |
|---|---|---|---|
| 0.5mg | 0.05 mL | 5 units | 40 |
| 1mg | 0.10 mL | 10 units | 20 |
| 2mg | 0.20 mL | 20 units | 10 |
| 4mg | 0.40 mL | 40 units | 5 |
| 8mg | 0.80 mL | 80 units | 2–3 |
| 12mg | 1.20 mL | 120 units | 1–2 |
A 30mg vial + 3mL bacteriostatic water = 10 mg/mL, providing ~50% more doses at each level. Use the RetaLABS reconstitution calculator for custom concentrations. Store reconstituted solution at 2–8°C; use within 4–6 weeks. Rotate injection sites (abdomen, thigh, upper arm) weekly.
Always use bacteriostatic water BAC water contains benzyl alcohol preservative, extending reconstituted stability to 4–6 weeks at 2–8°C. Sterile water has no preservative and must be used within 24 hours of vial opening.
Research Protocol Design Considerations
Key design notes from Phase 2 methodology applicable to Australian research protocols:
- Weekly interval: Retatrutide's ~6-day half-life makes once-weekly subcutaneous injection the appropriate interval. Consistent 7-day timing reduces pharmacokinetic variation.
- Dose hold: Escalation can be paused for an additional 4-week period at the current dose if GI events are significant. Holds do not constitute protocol discontinuation.
- Dose reduction: A one-step reduction (e.g. 8mg to 4mg) is permitted for intolerable AEs, with re-escalation once tolerability is re-established.
- Injection timing: No specific time-of-day requirement was used in Phase 2. Consistent weekly timing (same day each week) is standard practice.
- Body weight tracking: Phase 2 measured body weight weekly under standardised conditions (same time, fasted state).
For body composition data from Phase 2, see GLP-1 and Lean Mass Loss. For a cross-compound comparison, see Retatrutide vs Semaglutide.